Infliximab, a chimeric monoclonal antibody that neutralizes both soluble and membrane-bound TNF-α, is an effective treatment in autoimmune diseases such as psoriasis, RA and IBD, which can lead to long-term remission. This evidence concerns the gene TNF and psoriasis.